XT
XTX Topco Portfolio holdings
AUM
$2.41B
1-Year Return
23.26%
This Quarter Return
-5.14%
1 Year Return
+23.26%
3 Year Return
+47.46%
5 Year Return
–
10 Year Return
–
AUM
$586M
AUM Growth
+$27.7M
(+5%)
Cap. Flow
+$47.6M
Cap. Flow
% of AUM
8.13%
Top 10 Holdings %
Top 10 Hldgs %
4.62%
Holding
2,170
New
815
Increased
351
Reduced
337
Closed
665
Top Buys
| 1 |
Eli Lilly
LLY
|
+$3.35M |
| 2 |
Idexx Laboratories
IDXX
|
+$2.92M |
| 3 |
ATVI
Activision Blizzard Inc.
ATVI
|
+$2.88M |
| 4 |
W.W. Grainger
GWW
|
+$2.69M |
| 5 |
Visa
V
|
+$2.6M |
Top Sells
| 1 |
Boeing
BA
|
+$2.68M |
| 2 |
Oracle
ORCL
|
+$2.22M |
| 3 |
Nasdaq
NDAQ
|
+$2.13M |
| 4 |
Amgen
AMGN
|
+$2.11M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$2M |
Sector Composition
| 1 | Healthcare | 19.42% |
| 2 | Technology | 19.01% |
| 3 | Industrials | 14.45% |
| 4 | Consumer Discretionary | 12.64% |
| 5 | Financials | 10.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1026
Permian Resources
PR
$9.61B
| $194K | 0.03% |
+13,900
| New | +$194K |
|
1027
Relay Therapeutics
RLAY
$690M
| $193K | 0.03% |
22,931
+5,216
| +29% | +$43.9K |
|
1028
Cidara Therapeutics
CDTX
$1.66B
| $191K | 0.03% |
10,138
-12,319
| -55% | -$232K |
|
1029
Deluxe
DLX
$881M
| $191K | 0.03% |
+10,102
| New | +$191K |
|
|
TWOU
1030
DELISTED
2U, Inc.
TWOU
| $191K | 0.03% |
+2,575
| New | +$191K |
|
1031
James River Group
JRVR
$244M
| $189K | 0.03% |
+12,319
| New | +$189K |
|
1032
Innodata
INOD
$1.99B
| $189K | 0.03% |
22,134
+11,516
| +108% | +$98.2K |
|
1033
Aurinia Pharmaceuticals
AUPH
$1.68B
| $189K | 0.03% |
24,261
+10,700
| +79% | +$83.1K |
|
1034
P3 Health Partners
PIII
$28.1M
| $188K | 0.03% |
2,555
+1,220
| +91% | +$89.7K |
|
1035
ZIM Integrated Shipping Services
ZIM
$1.64B
| $187K | 0.03% |
17,874
+4,233
| +31% | +$44.2K |
|
1036
Sinclair Inc
SBGI
$972M
| $187K | 0.03% |
16,637
-6,917
| -29% | -$77.6K |
|
1037
ASE Group
ASX
$24B
| $186K | 0.03% |
24,751
-6,573
| -21% | -$49.4K |
|
1038
Altice USA
ATUS
$1.12B
| $186K | 0.03% |
56,825
+41,601
| +273% | +$136K |
|
1039
Wave Life Sciences
WVE
$1.11B
| $186K | 0.03% |
32,280
-29,181
| -47% | -$168K |
|
1040
Douglas Emmett
DEI
$2.79B
| $186K | 0.03% |
14,539
-16,707
| -53% | -$213K |
|
1041
Enhabit
EHAB
$399M
| $185K | 0.03% |
+16,441
| New | +$185K |
|
1042
Amylyx Pharmaceuticals
AMLX
$1.04B
| $185K | 0.03% |
+10,099
| New | +$185K |
|
1043
Ribbon Communications
RBBN
$675M
| $184K | 0.03% |
68,653
-75,363
| -52% | -$202K |
|
1044
JELD-WEN Holding
JELD
$537M
| $184K | 0.03% |
13,767
+2,998
| +28% | +$40.1K |
|
|
LGF.B
1045
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $184K | 0.03% |
23,337
+8,853
| +61% | +$69.7K |
|
1046
Sotera Health
SHC
$4.55B
| $183K | 0.03% |
+12,235
| New | +$183K |
|
1047
REV Group
REVG
$3.02B
| $182K | 0.03% |
11,346
-10,494
| -48% | -$168K |
|
1048
Precigen
PGEN
$1.13B
| $181K | 0.03% |
127,575
-135,471
| -52% | -$192K |
|
1049
Axogen
AXGN
$755M
| $181K | 0.03% |
36,228
+1,268
| +4% | +$6.34K |
|
|
KLRS
1050
Kalaris Therapeutics, Inc. Common Stock
KLRS
$72M
| $181K | 0.03% |
+3,654
| New | +$181K |
|